Form 4: Quest Diagnostics EVP Catherine T. Doherty Reports Stock Transactions
SEC Form 4 Filing
Catherine T. Doherty, EVP at Quest Diagnostics, reports the acquisition and disposal of company stock, including transactions to cover tax obligations and sales under a Rule 10b5-1 plan.
Summary
- Catherine T. Doherty, an EVP at Quest Diagnostics, filed a Form 4 detailing changes in her beneficial ownership of the company's stock.
- On March 3, 2025, she disposed of 394 shares at $173.74 to cover tax withholding obligations from vesting restricted stock units.
- On March 4, 2025, she sold 716 shares at $175.79 under a pre-arranged Rule 10b5-1 sales plan.
- Also on March 4, 2025, she acquired 10,380 shares at $173.74 related to a performance share award and disposed of 5,010 shares at $173.74 to cover tax withholding obligations from the settlement of the performance stock award.
- Following these transactions, Doherty directly owns 73,438 shares of Quest Diagnostics stock.
- Additionally, she indirectly owns 4,427 shares through the company's 401(k)/SDCP.
Sentiment
Score: 5
Explanation: This Form 4 filing is a neutral event, reflecting routine stock transactions by a company executive. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Monitoring insider transactions is a standard practice in the financial industry.
- Similar filings are made by executives at companies like Labcorp (LH) and Mayo Clinic Laboratories, providing a benchmark for understanding executive compensation and stock ownership trends within the diagnostics industry.
- The use of Rule 10b5-1 plans is common among corporate executives to avoid accusations of insider trading, aligning with practices seen at companies like Danaher (DHR) and Abbott Laboratories (ABT).
Key Dates
| Date | Description |
|---|---|
| 03/03/2025 | Disposition of 394 shares to cover tax withholding obligations. |
| 03/04/2025 | Sale of 716 shares under Rule 10b5-1 plan, acquisition of 10,380 shares from performance share award, and disposition of 5,010 shares to cover tax obligations. |
| 03/05/2025 | Date of signature by Sean D. Mersten, Attorney in Fact for Catherine T. Doherty. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.